Haleon, the consumer healthcare business that was spun off from GSK last week via a stock market listing, has posted its first set of trading figures as an independent company.
Over the six months to 30 June, its total revenue rose by 13.4% to £5.19bn with organic growth of 11.6% (3.7% price and 7.9% volume).
“Haleon delivered strong growth in the first half continuing the positive momentum seen since the start of year,” said Chief Executive Brian McNamara.
“This reflects the strength of our portfolio, continued innovation and excellent commercial execution across our markets.”
He stated that revenue had grown partly because of increased prices, but also overall sales performance of its operations around the world.
A strong cold and flu season boosted sales in the company’s respiratory unit (+46.7% organic), while its pain relief products (+11.7%) and vitamins (+11.9%) also performed well.
McNamara said: “With two strong quarters delivered and continued momentum into the second half, we now expect to deliver full-year organic revenue growth ahead of our medium-term guidance range (6-8%).”
After its listing last week, Haleon said it was now “100% focused on consumer health” and “driven by its purpose to deliver better everyday health with humanity”. The company – which owns brands such as Sensodyne, Voltarol, and Panadol – stated that it will continue to develop category-leading brands that address real consumer health needs, while focusing on future innovation across its entire portfolio.
